Safety Reading Notes

Read safety context beside the research guide.

The TRPM8 source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 30697147

PubMed For Dummies Article

TRPM8 Evidence Review: the long-form source walk-through

Quick read
  • TRPM8 currently has 61 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 30697147
  • The evidence classes most visible in the row language are insufficient (40), and mechanistic or pharmacological (21). PMID 33362478
  • The study-design language most visible in the row language is Narrative or expert review (26), Animal study (17), Meta-analysis or systematic evidence synthesis (3), and other mapped categories (5). PMID 27498155
  • The repeated topics are TRPM8 (15), TRP channel activity or ionotropic cannabinoid target mechanisms (11), TRPA1 (7), receptor, target, metabolic, or pharmacology mechanisms (6), and other mapped categories (22), which tells the reader where to start opening PubMed and DOI links. PMID 26698193

Start with the research question

TRPM8 is built from 61 source-backed evidence row(s) and 28 research source(s). The current evidence classes read as insufficient (40), and mechanistic or pharmacological (21), and the study-design language most often reads as Narrative or expert review (26), Animal study (17), Meta-analysis or systematic evidence synthesis (3), and other mapped categories (5). PMID 30697147

The row-level question is not simply whether TRPM8 is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are TRPM8 (15), TRP channel activity or ionotropic cannabinoid target mechanisms (11), TRPA1 (7), receptor, target, metabolic, or pharmacology mechanisms (6), and other mapped categories (22). PMID 18354058

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 33155670

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 33168643

Mechanistic evidence 20 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 33629929

Limits and uncertainty 43 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 35483477

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 34259916

Where this page has the most source density

The largest bucket surfaced for this page is TRP channel activity or ionotropic cannabinoid target mechanisms. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is TRPM8, which gives readers another way to see what the literature repeatedly circles. PMID 30697147

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 18354058

Bucket chapters: what the literature is circling

TRP channel activity or ionotropic cannabinoid target mechanisms

6 research sources 6 rows (214-364) Mechanistic research summary: insufficient (5), mechanistic or pharmacological (1)

TRPM8 appears in rows about TRP channel activity or ionotropic cannabinoid target mechanisms mechanisms. It currently draws from 6 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 30697147

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 30697147

  • Evidence row 214

    THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mech... PMID 30697147

  • Evidence row 364

    THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome... PMID 21175579

TRPM8

4 research sources 4 rows (1049-1056) Mechanistic research summary: insufficient (2), mechanistic or pharmacological (2)

TRPM8 appears in rows about TRPM8 mechanisms. It currently draws from 4 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 18354058

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 18354058

  • Evidence row 1049

    THC modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 18354058

  • Evidence row 1056

    THC modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 28120232

Receptor, target, metabolic, and pharmacology mechanisms

3 research sources 3 rows (568-572) Mechanistic research summary: insufficient (1), mechanistic or pharmacological (2)

TRPM8 appears in rows about Receptor, target, metabolic, and pharmacology mechanisms mechanisms. It currently draws from 3 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 40967679

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 40967679

  • Evidence row 568

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, target, metabolic, or pharmacology me... PMID 40967679

  • Evidence row 572

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target,... PMID 40540228

TRP channel activity or ionotropic cannabinoid target mechanisms

3 research sources 3 rows (215-361) Mechanistic research summary: insufficient (2), mechanistic or pharmacological (1)

TRPM8 appears in rows about TRP channel activity or ionotropic cannabinoid target mechanisms mechanisms. It currently draws from 3 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 33362478

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 33362478

  • Evidence row 215

    CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 33362478

  • Evidence row 361

    CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mech... PMID 35483477

TRPA1

3 research sources 3 rows (1031-1047) Mechanistic research summary: insufficient (2), mechanistic or pharmacological (1)

TRPM8 appears in rows about TRPA1 mechanisms. It currently draws from 3 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 35483477

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 35483477

  • Evidence row 1031

    CBD modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 35483477

  • Evidence row 1047

    CBD modulates TRPA1; evidence class: mechanistic or pharmacological (outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 38408345

TRPA1

3 research sources 3 rows (1030-1033) Mapped evidence with interpretation limits: insufficient (3)

TRPM8 appears in rows about TRPA1 mechanisms. It currently draws from 3 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 30697147

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 30697147

  • Evidence row 1030

    THC modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 30697147

  • Evidence row 1033

    THC modulates TRPA1; evidence class: insufficient (outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 29240420

TRPM8

3 research sources 3 rows (1054-1060) Mapped evidence with interpretation limits: insufficient (3)

TRPM8 appears in rows about TRPM8 mechanisms. It currently draws from 3 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 19070372

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 19070372

  • Evidence row 1054

    Cannabinoids modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 19070372

  • Evidence row 1060

    Cannabinoids modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 21622235

TRPM8

3 research sources 3 rows (1048-1058) Mechanistic research summary: insufficient (2), mechanistic or pharmacological (1)

TRPM8 appears in rows about TRPM8 mechanisms. It currently draws from 3 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 35483477

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 35483477

  • Evidence row 1048

    CBD modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 35483477

  • Evidence row 1058

    CBD modulates TRPM8; evidence class: mechanistic or pharmacological (outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 38408345

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (20 row(s)), and safety/tolerability context (3 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 30697147

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 18354058

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 18354058
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 21175579
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 40967679

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 30697147

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 18354058

Source-reading checklist for TRPM8

  1. Open the linked PubMed or DOI record. PMID 40540228
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 42352060
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 25269802
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 29240420
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 19070372

Source Notes

TRPM8 source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 214

    THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 30697147

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
  2. Evidence row 215

    CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 33362478

    Evidence class: insufficient. Source: An Analysis of the Putative CBD Binding Site in the Ionotropic Cannabinoid Receptors.
  3. Evidence row 216

    THCV modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 27498155

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.
  4. Evidence row 357

    THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 26698193

    Evidence class: insufficient; Study design: Narrative or expert review. Source: An Introduction to the Endogenous Cannabinoid System.
  5. Evidence row 358

    Cannabinoids modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 33155670

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Temperature-sensitive transient receptor potential vanilloid channels: structural insights into ligand-dependent activation.
  6. Evidence row 359

    THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 33168643

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The Pharmacological Case for Cannabigerol.
  7. Evidence row 360

    CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 33629929

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4.
  8. Evidence row 361

    CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 35483477

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological effects of cannabidiol by transient receptor potential channels.
  9. Evidence row 362

    THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 34259916

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
  10. Evidence row 363

    THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 18354058

    Evidence class: insufficient; Study design: Animal study. Source: Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8.
  11. Evidence row 364

    THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 21175579

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
  12. Evidence row 517

    CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 40967679

    Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.
  13. Evidence row 548

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 40540228

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities.
  14. Evidence row 558

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 42352060

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.
  15. Evidence row 568

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 40967679

    Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.
  16. Evidence row 570

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 25269802

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.
  17. Evidence row 572

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 40540228

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities.
  18. Evidence row 648

    CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 42352060

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.
  19. Evidence row 663

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40967679

    Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.
  20. Evidence row 764

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 27498155

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.
  21. Evidence row 765

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 21175579

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
  22. Evidence row 784

    THCV studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or immune outcomes). PMID 27498155

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.
  23. Evidence row 927

    THC modulates GPR55; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 34259916

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
  24. Evidence row 971

    THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 30697147

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
  25. Evidence row 972

    THC modulates TRPV1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 34259916

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
  26. Evidence row 989

    THC modulates TRPV2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology). PMID 30697147

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
  27. Evidence row 990

    THC modulates TRPV2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology). PMID 34259916

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
  28. Evidence row 996

    THC modulates TRPV2; evidence class: insufficient (outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology). PMID 29240420

    Evidence class: insufficient. Source: Iodine-Promoted Aromatization of p-Menthane-Type Phytocannabinoids.
  29. Evidence row 997

    Cannabinoids modulates TRPV2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology). PMID 19070372

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia.
  30. Evidence row 1004

    THC modulates TRPV3; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology). PMID 30697147

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
  31. Evidence row 1005

    CBD modulates TRPV3; evidence class: insufficient (outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology). PMID 33362478

    Evidence class: insufficient. Source: An Analysis of the Putative CBD Binding Site in the Ionotropic Cannabinoid Receptors.
  32. Evidence row 1006

    THCV modulates TRPV3; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology). PMID 27498155

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.
  33. Evidence row 1015

    THC modulates TRPV3; evidence class: mechanistic or pharmacological (outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology). PMID 40141324

    Evidence class: mechanistic or pharmacological. Source: The Impact of a Quinone Scaffold on Thermo-TRPs Modulation by Dimethylheptyl Phytocannabinoids.
  34. Evidence row 1016

    THC modulates TRPV4; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 30697147

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
  35. Evidence row 1017

    CBD modulates TRPV4; evidence class: insufficient (outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 33362478

    Evidence class: insufficient. Source: An Analysis of the Putative CBD Binding Site in the Ionotropic Cannabinoid Receptors.
  36. Evidence row 1020

    Cannabinoids modulates TRPV4; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 19070372

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia.
  37. Evidence row 1024

    Cannabinoids modulates TRPV4; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 29470146

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Toward an effective peripheral visceral analgesic: responding to the national opioid crisis.
  38. Evidence row 1025

    Endocannabinoids modulates TRPV4; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 26990140

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Potential Future Pharmacological Treatment of Bladder Dysfunction.
  39. Evidence row 1026

    Cannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 41802611

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Peripheral cannabinoid receptor activation attenuates frostbite-induced chronic pain via modulation of TRP channels, neuroinflammation, and autophagy.
  40. Evidence row 1030

    THC modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 30697147

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
  41. Evidence row 1031

    CBD modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 35483477

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological effects of cannabidiol by transient receptor potential channels.
  42. Evidence row 1032

    THC modulates TRPA1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 34259916

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
  43. Evidence row 1033

    THC modulates TRPA1; evidence class: insufficient (outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 29240420

    Evidence class: insufficient. Source: Iodine-Promoted Aromatization of p-Menthane-Type Phytocannabinoids.
  44. Evidence row 1034

    Cannabinoids modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 19070372

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia.
  45. Evidence row 1045

    CBD modulates TRPA1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 35605018

    Evidence class: insufficient; Study design: Systematic review. Source: Systematic Review on Transdermal/Topical Cannabidiol Trials: A Reconsidered Way Forward.
  46. Evidence row 1047

    CBD modulates TRPA1; evidence class: mechanistic or pharmacological (outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 38408345

    Evidence class: mechanistic or pharmacological. Source: Phytochemical Characterization and TRPA1/TRPM8 Modulation Profile of the Cannabigerol-Rich Cannabis sativa L. Chemotype IV.
  47. Evidence row 1048

    CBD modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 35483477

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological effects of cannabidiol by transient receptor potential channels.
  48. Evidence row 1049

    THC modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 18354058

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8.
  49. Evidence row 1050

    THC modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 21175579

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
  50. Evidence row 1051

    CBG modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 25269802

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.
  51. Evidence row 1052

    CBG modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 40540228

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities.
  52. Evidence row 1053

    THC modulates TRPM8; evidence class: insufficient (outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 29240420

    Evidence class: insufficient. Source: Iodine-Promoted Aromatization of p-Menthane-Type Phytocannabinoids.
  53. Evidence row 1054

    Cannabinoids modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 19070372

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia.
  54. Evidence row 1055

    Cannabinoids modulates TRPM8; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 29470146

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Toward an effective peripheral visceral analgesic: responding to the national opioid crisis.
  55. Evidence row 1056

    THC modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 28120232

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular Targets of the Phytocannabinoids: A Complex Picture.
  56. Evidence row 1057

    CBD modulates TRPM8; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 35605018

    Evidence class: insufficient; Study design: Systematic review. Source: Systematic Review on Transdermal/Topical Cannabidiol Trials: A Reconsidered Way Forward.
  57. Evidence row 1058

    CBD modulates TRPM8; evidence class: mechanistic or pharmacological (outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 38408345

    Evidence class: mechanistic or pharmacological. Source: Phytochemical Characterization and TRPA1/TRPM8 Modulation Profile of the Cannabigerol-Rich Cannabis sativa L. Chemotype IV.
  58. Evidence row 1059

    Endocannabinoids modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 39684707

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: TRPM8's Role in the Shift Between Opioid and Cannabinoid Pathways in Electroacupuncture for Inflammatory Pain in Mice.
  59. Evidence row 1060

    Cannabinoids modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 21622235

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Effects of opioids, cannabinoids, and vanilloids on body temperature.
  60. Evidence row 1061

    Endocannabinoids modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 17428469

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids.
  61. Evidence row 1062

    CBG modulates TRPM8; evidence class: mechanistic or pharmacological (outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 30077611

    Evidence class: mechanistic or pharmacological. Source: Iodine-mediated cyclization of cannabigerol (CBG) expands the cannabinoid biological and chemical space.